Press enter to see results or esc to cancel.

Vivet Therapeutics

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. It is focused on optimizing gene therapy through collaborating with the Fundacion para la Investigacion Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long-term expression. Vivet’s …

Continue Reading

VarmX

A spin-off from the Leiden University Medical Center (LUMC), VarmX is a clinical-stage pharmaceutical company that is focusing on the development of therapies in the field of hemostasis and thrombosis. VarmX’s lead compound, VMX-C001, is a modified recombinant human blood factor X based on the venom of the Australian brown snake, Pseudonaja textilis. The compound …

Continue Reading

NorthSea Therapeutics

NorthSea Therapeutics is a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic, inflammatory and fibrotic diseases. It is working to make structurally engineered fatty acids, or SEFAs, a novel class of drugs that are meant to unlock the therapeutic potential of fatty acids by increasing organ-specificity …

Continue Reading

Minoryx Therapeutics

Minoryx Therapeutics is a late-stage biotech company focused on the development of treatments for orphan central nervous system (CNS) diseases with high unmet medical needs. The company’s lead program, leriglitazone (MIN-102) — a novel, brain penetrant and selective PPAR gamma agonist — is being developed in X-linked Adrenoleukodystrophy (X-ALD) and other orphan CNS diseases. In …

Continue Reading

Inbiomotion

A spin-off of IRB Barcelona and ICREA research labs, Inbiomotion is focused on providing a unique companion diagnostic solution addressing an urgent and unmet medical need in the personalized adjuvant treatment of early-stage breast cancer patients. The company’s unique diagnostic assay is based on a highly selective single-gene predictive biomarker. Data generated thus far points …

Continue Reading

Cytoki Pharma

Cytoki Pharma is engaged in the development of protein drugs for diseases characterized by epithelial injury. To that end, the company is advancing a long-acting Interleukin-22 (IL-22) variant to clinical testing with the initial focus on Inflammatory Bowel Disease (IBD). The lead compound is selected from a full program of therapeutic IL-22 variants based on …

Continue Reading

AELIX Therapeutics

AELIX Therapeutics is a clinical-stage biotechnology company focused on the development of a therapeutic HIV vaccine to be used in cure and eradication strategies. AELIX Therapeutics is a spin-off of HIVACAT, a Catalan public-private consortium conducting cutting-edge research in the field of AIDS. The HIVACAT program is led by IrsiCaixa Aids Research Institute and the …

Continue Reading

Ona Therapeutics

A spin-off from ICREA and Advanced Studies and the IRB Institute for Research in Biomedicine, ONA Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting lipid metabolism in order to treat advanced (metastatic) cancer. The company’s technology is based on pioneering work from Dr Aznar-Benitah published in Nature …

Continue Reading

Nuage Therapeutics

Nuage Therapeutics leverages chemical biology and biomolecular condensation to develop selective drugs targeting proteins with disordered regions for challenging indications to improve patient’s life. Specifically, it uses a proprietary assay to discover new drugs for the treatment of castration-resistant prostate cancer.

Continue Reading

AgomAb Therapeutics

Founded through a collaboration between argenx and the University of Torino, Italy – Agomab is translating deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, it is …

Continue Reading

Splice Bio

Formerly called ProteoDesign, SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. Its platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. In this novel approach, engineered inteins catalyze highly efficient protein …

Continue Reading